Stock TVGN TEVOGEN BIO HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tevogen Bio Holdings Inc.

Equities

TVGN

US88165K1016

Delayed Nasdaq
Other stock markets
 13:25:14 2024-06-04 EDT 		5-day change 1st Jan Change
0.7872 USD -0.61% Intraday chart for Tevogen Bio Holdings Inc. -0.78% -92.93%
05-13 Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday MT
05-13 Top Premarket Gainers MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Tevogen Bio Reports First Quarter 2024 Financial Results
GL
Tevogen Bio Reports First Quarter 2024 Financial Results
AQ
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
GL
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday
MT
Top Premarket Gainers
MT
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
GL
Tevogen Bio Holdings Inc. announced that it expects to receive $50 million in funding
CI
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
GL
Sector Update: Health Care Stocks Higher in Afternoon Trading
MT
Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination
MT
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
GL
Top Premarket Gainers
MT
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
GL
Top Premarket Gainers
MT
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
GL
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
CI
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
GL
Tevogen Bio Holdings Inc. amended terms of the transaction
CI
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
BU
Tevogen Bio Holdings Announces TVGN 489, its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TVGN Stock
  4. News Tevogen Bio Holdings Inc.